Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPITL: Combined Drug Approach in Liver Transplantation
NCT02251041Phase 2Completed
- Sponsor
- UZ Leuven
- Start
- Sep 2014
- Primary completion
- Feb 2019
- Modality
- Orthosteric Ligands, Erythropoietins, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of antithrombin III, infliximab, apotransferrin, epoetin beta, c1-esterase inhibitor in ischemia-reperfusion injury (IRI), sponsored by UZ Leuven. Started Sep 2014; status: completed.
02
Drugs
antithrombin IIIinfliximabapotransferrinepoetin betac1-esterase inhibitor
03
Conditions
ischemia-reperfusion injury (IRI)
Beyond the preview
Go deeper on NCT02251041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02251041.